Kirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)

NEW YORK–(BUSINESS WIRE)–$RPTX #ClassActionLawsuit–The law firm of Kirby McInerney LLP is investigating potential claims against Repare Therapeutics Inc. (“Repare” or the “Company”) (NASDAQ: RPTX). The investigation concerns whether Repare and/or certain of its officers have violated the federal securities laws and/or engaged in other unlawful business practices.
[Click here to learn more about the investigation]
On January 25, 2024, Repare revealed a $40 million milestone payment from its collaboration with Roche for the development and commercialization of camonsertib, an ATR inhibitor. On February 12, 2024, Repare issued a press release “announc[ing] . . . that it will regain global development and commercialization rights to camonsertib…following termination of its collaboration agreement with Roche.” According to the press release, “Roche notified Repare that, effective May 7, 2024, it is terminating its worldwide license and collaboration agreement for the development and commercialization of camonsertib following a review of Roche’s pipeline and evolving external factors.” On this news, the price of Repare shares declined by $1.31 per share, or approximately 15.58%, from $8.41 per share on February 12, 2024 to close at $7.10 on February 13, 2024.
If you purchased or otherwise acquired Repare securities, have information, or would like to learn more about this investigation, contact Thomas W. Elrod of Kirby McInerney LLP by email at investigations@kmllp.com, or by filling out this CONTACT FORM, to discuss your rights or interests with respect to these matters without any cost to you.
Kirby McInerney LLP is a New York-based plaintiffs’ law firm concentrating in securities, antitrust, whistleblower, and consumer litigation. The firm’s efforts on behalf of shareholders in securities litigation have resulted in recoveries totaling billions of dollars.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. Contacts
Kirby McInerney LLP
Thomas W. Elrod, Esq.
212-699-1180
https://www.kmllp.cominvestigations@kmllp.com